'Freeing data from the silos' collaboration will combine IDBS's pharmaceutical data management tools including the E-WorkBook (EWB) technology with ISD's state-of-the-art data K3 integration platform
IDBS and In Silico Discovery have announced a strategic partnership aimed at integrating all drug discovery data and providing flexible access irrespective of where it is stored.
Researchers will be able to use one compliant, safe and flexible portal to non-invasively access data from multiple stores such as corporate silos, legacy databases and web-based repositories.
This approach enables researchers to construct project-specific queries via creation of a virtual data warehouse - a collection of information made from numerous sources, which does not alter or affect the source.
This way of non-invasive information recovery negates the need to transform or alter the original data format - relevant data is made available to the end user to support knowledge and ultimately better decision-making.
Brian Donnelly, CEO of ISD said: "K3 represents a unique technology developed by leading academics and with proven commercial applicability.
"Combining this with IDBS's applications and domain expertise we can now leverage this potential to address the problems being presented by Systems Biology and Translational Medicine".
Founder and CEO of IDBS, Neil Kipling, added: "We are well used to handling the volume and complexity of data generated in modern drug discovery.
"The challenge today's researchers face is that relevant data tends to be widely distributed in numerous private and public data silos and includes many different data types; chemistry, biology and image data.
"Getting access to this data is cumbersome and time consuming.
"The combination of EWB with K3 through this collaboration gives researchers the power to easily access all applicable information from one single point, and importantly as part of their day to day workflow."
